Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by F. Re
Phase Ii Fil-Ptcl13 Study of Romidepsin-Choep Followed by High-Dose Chemotherapy and Transplantation in Untreated Peripheral T-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pet-Driven Radiotherapy in Patients With Low Risk Diffuse Large B-Cell Lymphoma (Dlbcl): The Dlcl10 Multicenter Phase 2 Trial by Fondazione Italiana Linfomi (Fil)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Elderly Project by the Fondazione Italiana Linfomi: A Prospective Comprehensive Geriatric Assessment (Cga) of 1353 Elderly Patients With Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
